Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab versus cetuximab with mFOLFOX6 or FOLFIRI as first-line treatment for unresectable or metastatic left-sided RAS/BRAF wild-type colorectal cancer
MOH_2024-09-26_013666Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Amivantamab with mFOLFOX6 or FOLFIRI with Cetuximab with mFOLFOX6 or FOLFIRI (2 arms). Started Sep 2024; status: recruiting.
02
Drugs
amivantamabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2024-09-26_013666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-26_013666.